- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00525486
Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery
Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery:A Prospective Interventional Study
To evaluate the treatment efficacy and safety usig extended release nifedipine, as maintenance therapy to pregnant women who were hospitalized and treated for preterm labor until 34 weeks' gestation. After the PTL will stop, we will randomize these women for the treatment group and the control (no treatment) group.
The main outcome will be preterm delivery before 34 weeks' gestation. the secondary outcome will be the side effects of the medication and the newborn/mother health variables.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- pregnancy week 24-33
- Singleton pregnancy
- After successful treatment to stop PTL
Exclusion Criteria:
- Contraindications for Nifedipine extended release treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
The treated group of pregnant women, after having successful treatment for PTL
|
Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
Other Names:
|
No Intervention: B
The no treatment arm of women treated with tocolysis for PTL.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yuri Perlitz, MD, The Baruch Padeh Medical Center, Poria, Israel.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pregnancy Complications
- Obstetric Labor Complications
- Premature Birth
- Obstetric Labor, Premature
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Nifedipine
Other Study ID Numbers
- PTL prevention Nifedipine
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Labor
-
Istanbul University - Cerrahpasa (IUC)CompletedPreterm Labor | Preterm Spontaneous Labor With Preterm Delivery | Preterm Labor With Preterm Delivery in Third TrimesterTurkey
-
University Hospital, Strasbourg, FranceRecruitingPreterm Delivery | Threatened Preterm LaborFrance
-
Ain Shams UniversityRecruitingPreterm Labor With Preterm DeliveryEgypt
-
University of Modena and Reggio EmiliaNot yet recruitingPreterm Labor With Preterm DeliveryItaly
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Konya Meram State HospitalRecruitingPregnancy Preterm | Preterm Labor Without DeliveryTurkey
-
e-Bio CorpRecruitingPreterm Labor | PreTerm Birth | Preterm Labor With Delivery NosUnited States
-
Hospital Clinico Universitario de SantiagoFundación Ramón DomínguezWithdrawnThreatened Preterm Labor
-
Tel-Aviv Sourasky Medical CenterUnknownLabor Preterm Multiple
-
Shiraz University of Medical SciencesCompletedManaging Preterm Labor
Clinical Trials on Nifedipine extended release
-
Cao YuUnknownTherapeutic EquivalencyChina
-
Actavis Inc.Completed
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Actavis Inc.Completed
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States
-
SocraTec R&D GmbHSocraMetrics GmbHCompletedBioavailability, Therapeutical Indication Not StudiedGermany
-
Murdoch Childrens Research InstituteRecruitingNeoplasms | Bone Marrow TransplantationAustralia
-
Luye Pharma Group Ltd.CompletedMajor Depressive Disorder (MDD)China